<p>Drug major Glenmark Pharma on Wednesday said it has received final approval from the US health regulator for Topiramate extended-release capsules, used to treat certain types of seizures.</p>.<p>The approved product is a generic version of Qudexy XR Capsules of Upsher-Smith Laboratories, LLC.</p>.<p>Glenmark Pharmaceuticals Ltd has received final approval from the United States Food and Drug Administration (USFDA) for Topiramate extended-release capsules USP in the strengths of 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, Glenmark said in a regulatory filing.</p>.<p>Quoting IQVIA sales data for the 12-month period ended December 2020, Glenmark Pharmaceuticals said Qudexy extended-release capsules market achieved annual sales of approximately $120 million.</p>.<p>The company's current portfolio consists of 169 products authorised for distribution in the US market and 43 abbreviated new drug applications (ANDAs) pending approval with the USFDA.</p>.<p>Shares of Glenmark Pharmaceuticals were trading 2.41 per cent higher at Rs 499.10 apiece on the BSE.</p>
<p>Drug major Glenmark Pharma on Wednesday said it has received final approval from the US health regulator for Topiramate extended-release capsules, used to treat certain types of seizures.</p>.<p>The approved product is a generic version of Qudexy XR Capsules of Upsher-Smith Laboratories, LLC.</p>.<p>Glenmark Pharmaceuticals Ltd has received final approval from the United States Food and Drug Administration (USFDA) for Topiramate extended-release capsules USP in the strengths of 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, Glenmark said in a regulatory filing.</p>.<p>Quoting IQVIA sales data for the 12-month period ended December 2020, Glenmark Pharmaceuticals said Qudexy extended-release capsules market achieved annual sales of approximately $120 million.</p>.<p>The company's current portfolio consists of 169 products authorised for distribution in the US market and 43 abbreviated new drug applications (ANDAs) pending approval with the USFDA.</p>.<p>Shares of Glenmark Pharmaceuticals were trading 2.41 per cent higher at Rs 499.10 apiece on the BSE.</p>